Viral transduction of primary schwann cells using a cre-lox system to regulate glial cell line-derived neurotrophic factor expression

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Peripheral nerve injuries are common and can lead to major disabilities. Despite refinement in surgical techniques to reconstruct nerve injuries, complete functional recovery following nerve regeneration is rare. Therefore, nonsurgical strategies that enhance functional recovery following injury are sought. The advances of the potential therapeutic glial cell line-derived neurotrophic factor (GDNF) are discussed including limitations to its clinical translation. As a tool to expand understanding of exogenous GDNF therapies, Schwann cells (SCs) with inducible GDNF expression have been developed. These transgenic SCs can regulate GDNF overexpression via tetracycline family antibiotics allowing for spatial and temporal regulation of GDNF. This chapter provides an overview of peripheral nerve biology including injury and regeneration and the clinical state of the field to improve regenerative outcomes. This chapter then describes methods and anticipated results to generate primary SCs capable of GDNF expression.

Original languageEnglish
Title of host publicationGene Therapy in Neurological Disorders
PublisherElsevier
Pages327-344
Number of pages18
ISBN (Electronic)9780128098134
ISBN (Print)9780128098219
DOIs
StatePublished - Jan 1 2018

Keywords

  • Glial cell line-derived neurotrophic factor
  • Growth factor
  • Lentivirus
  • Nerve regeneration
  • Neurotrophic factor
  • Peripheral nerve
  • Schwann cell
  • Tetracycline

Fingerprint Dive into the research topics of 'Viral transduction of primary schwann cells using a cre-lox system to regulate glial cell line-derived neurotrophic factor expression'. Together they form a unique fingerprint.

  • Cite this